---
title: "CLSA Raises BEONE MEDICINES  TP to HKD336.8, 3Q Results Beat Expectations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304946248.md"
description: "CLSA raised BEONE MEDICINES' target price to HKD336.8 and upgraded US TP to USD561.3, maintaining an Outperform rating. This follows Q3 results beating expectations, with revenue up 33.8% YoY to USD1.89 billion and net profit surging 208.2% to USD385 million, driven by strong Brukinsa sales. Management also raised full-year 2026 revenue guidance to USD6.9-7 billion. CLSA increased its 2026-2028 revenue and profit forecasts accordingly."
datetime: "2026-11-10T03:10:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304946248.md)
  - [en](https://longbridge.com/en/news/304946248.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304946248.md)
generator: "portal-rs"
---

# CLSA Raises BEONE MEDICINES  TP to HKD336.8, 3Q Results Beat Expectations

CLSA published a research report stating that BEONE MEDICINES (06160.HK) +2.200 (+0.886%) Short selling $359.99M; Ratio 40.240% 's 3Q revenue rose 33.8% YoY to USD1.89 billion, while net profit surged 208.2% YoY to USD385 million, both exceeding market expectations, mainly driven by strong sales of Brukinsa.

The broker said global sales of Brukinsa increased 33.7% YoY to USD1.4 billion, with US sales exceeding USD1 billion for the first time, up 36.1% YoY. According to CLSA estimates, Brukinsa's US BTK market share further increased from 43.1% in 2Q to 45.7% in 3Q. Following guidance upgrades in 1Q and 2Q, management again raised full-year 2026 revenue guidance from USD6.6 billion-USD6.8 billion to USD6.9 billion-USD7 billion, and raised GAAP operating income guidance from USD1 billion-USD1.1 billion to USD1.2 billion-USD1.3 billion.

CLSA raised its 2026-2028 revenue forecasts for BEONE MEDICINES by 3.9%, 2.2% and 1.9%, respectively, and increased net profit forecasts by 13.3%, 3.5% and 2.1%, respectively. It lifted the TP for BEONE MEDICINES (06160.HK) +2.200 (+0.886%) Short selling $359.99M; Ratio 40.240% from HKD321.7 to HKD336.8, and raised the US stock TP for BeOne Medicines Ltd. (ONC.US) from USD522.5 to USD561.3, while maintaining an Outperform rating.(gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-09 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

### Related Stocks

- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)

## Related News & Research

- [BeOne Medicines: Five solid-tumor programs advance as strong cash flow funds continued pipeline investment](https://longbridge.com/en/news/305810947.md)
- [BeOne commits $3M to expand CLL Society patient education pact](https://longbridge.com/en/news/305853990.md)
- [BeOne Medicines (ONC) Priority Review And Earnings Put Valuation Back In Focus](https://longbridge.com/en/news/304861942.md)
- [Why BeOne Medicines Stock Is In Focus After Earnings Beat And Raised Guidance](https://longbridge.com/en/news/304730912.md)
- [BREAKINGVIEWS-Biotech rising star has lifeline from geopolitics](https://longbridge.com/en/news/304799087.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**